Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GLENMARK.NS
Strong BuyPremium GrowerGlenmark Pharmaceuticals Limited · Healthcare · India · $7.4B · Avg Vol: $13M/d
94
StockRankGet insider-trade alerts
Q
82
V
36
M
80
P/E (TTM)
38.3x
ROE
13.0%
D/E
0.1x
Dividend %
0.1%
COMPANY DESCRIPTION
Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 114.3B | 116.4B | 131.5B | 167.1B | 13.5% | 178.0B | 165.2B | 184.1B | 5.0% |
| EPS (INR) | 10.53 | -53.22 | 37.11 | 48.26 | 66.1% | 63.81 | 37.36 | 45.62 | -2.8% |
| Shares | 282.2M | 282.2M | 282.2M | 282.2M | +0.0% | 282.2M | — | — | — |
| Debt | 46.1B | 12.3B | 24.7B | 5.9B | -49.5% | 6.0B | — | — | — |
| Equity | 94.7B | 78.5B | 88.5B | 105.1B | 3.5% | — | — | — | — |
| Op CF | 6.3B | -2.7B | -8.3B | 34.5B | 76.6% | 34.6B | — | — | — |
| Inv CF | -5.3B | 45.6B | 20.9M | -12.8B | — | — | — | — | — |
| Fin CF | -774.6M | -39.1B | 7.9B | -27.1B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+11.3%
SMA 50SMA 200
Close
$25.52
RSI (14)
64.3
52W High
$26.56
From 52W High
1.0%
SCORE BREAKDOWN
Quality
82
ROIC
20.2%90.4
ROE
13.0%78.2
GP/Assets
64.1%92.4
Op. Margin
15.7%76.2
FCF/Assets
10.5%87.8
Piotroski
999.1
Int. Cover
13.4x66.0
D/E Ratio
0.06x69.7
Current Ratio
1.77x33.8
Value
36
P/E (TTM)
38.3x29.8
EV/EBITDA
14.3x50.5
P/FCF
33.6x43.5
P/B
6.5x20.7
P/S
3.9x49.4
Div Yield
0.1%2.3
Momentum
80
52W High %
96%95.4
RS 6M
11%74.8
SMA 50/200
1.06x69.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+54%57.1
Q Growth
930%98.2
FUNDAMENTALS
Market Cap
$7.4B
P/E (Forward)
24.9x
Gross Margin
71.9%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GLENMARK.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GLENMARK.NS | Glenmark Pharmaceuticals Limited(you) | $7.4B | 94 | Strong Buy |
| LUPIN.NS | Lupin Limited | $10.2B | 91 | Strong Buy |
| IPCALAB.NS | Ipca Laboratories Limited | $5.3B | 91 | Strong Buy |
| AUROPHARMA.NS | Aurobindo Pharma Limited | $10.3B | 91 | Strong Buy |
| GLAND.NS | Gland Pharma Limited | $5.1B | 88 | Strong Buy |
| ABBOTINDIA.NS | Abbott India Limited | $5.7B | 79 | Buy |
| AJANTPHARM.NS | Ajanta Pharma Limited | $4.7B | 79 | Buy |
| EMCURE.NS | Emcure Pharmaceuticals Limited | $3.9B | 81 | Strong Buy |
| LAURUSLABS.NS | Laurus Labs Limited | $11.1B | 75 | Buy |
| ALKEM.NS | Alkem Laboratories Limited | $6.5B | 69 | Buy |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%